GlassScriptPhysician profile
William B Lawson
NPI 1750499406
$7,952.13
in general payments reported to CMS, 2019-2025
15 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $3,456 · 2021: $2,684 · 2022: $289 · 2023: $82.50 · 2024: $147 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $6,195.60 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $534.88 | 2019 | |
| Lundbeck LLC | $191.81 | 2019-2025 | Rexulti |
| Alkermes, INC. | $186.47 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.95 | 2021-2022 | |
| Abbvie INC. | $178.78 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $166.69 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $125.27 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.35 | 2024 | Pomalyst |
| Otsuka America Pharmaceutical, INC. | $34.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.66 | 2019 | |
| Indivior INC. | $23.09 | 2022 | |
| Sage Therapeutics, LLC | $21.99 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.